Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29037548 | 1.00 | OPRM1 (0.66) | OPRM1OPRD1OPRK1 | |
| SCHEMBL31347655 | 1.00 | OPRM1 (0.66) | OPRM1OPRD1OPRK1 | |
| SCHEMBL13563441 | 1.00 | OPRM1 (0.66) | OPRM1OPRD1OPRK1 | |
| SCHEMBL3400800 | 0.96 | OPRM1 (0.67) | OPRM1OPRD1OPRK1 | |
| SCHEMBL13118010 | 0.96 | OPRM1 (0.67) | OPRM1OPRD1OPRK1 | |
| SCHEMBL23114234 | 0.96 | OPRM1 (0.67) | OPRM1OPRD1OPRK1 | |
| SCHEMBL18951647 | 0.93 | XIAP (0.61) | OPRM1OPRD1OPRK1 | |
| SCHEMBL31519795 | 0.91 | OPRM1 (0.69) | OPRM1OPRD1OPRK1 | |
| SCHEMBL38658663 | 0.90 | OPRM1 (0.78) | OPRM1OPRD1OPRK1 | |
| SCHEMBL1662052 | 0.88 | OPRM1 (0.61) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| US-9518083-B2 | Gadd45beta targeting agents | IMPERIAL INNOVATIONS LIMITED (GB) | 2016-12-13 | — | — | US | disclosed |
| US-20150368294-A1 | GADD45BETA TARGETING AGENTS | IP2IPO INNOVATIONS LIMITED (GB) | 2015-12-24 | — | — | US | disclosed |
| US-8993717-B2 | Gadd45beta targeting agents | IMPERIAL INNOVATIONS LIMITED (GB) | 2015-03-31 | — | — | US | disclosed |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | MCL1, DDIT3, MAP2K7 | OPRM1 4699/4885OPRD1 4634/4885OPRK1 4322/4885 |
| US-20150368294-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | OPRM1 2112/4885OPRD1 2444/4885OPRK1 1949/4885 |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | OPRM1 2112/4885OPRD1 2444/4885OPRK1 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.